RUNX1 and myelodysplastic syndrome: In addition, point mutations in AML1/RUNX1 were observed at a high frequency in myelodysplastic syndrome (MDS)/AML cases in radiation-exposed residents near the Semipalatinsk Nuclear Test Site as compared with MDS/AMLs from unexposed individuals [33].